This inventor holds 1 USPTO granted patent and 3 published patent applications. Top assignee: Y-Biologics Inc.. Active years: 2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2024
Title: **Inventor Dong Jung Lee and His Contributions to Immunotherapy**
Introduction
Dong Jung Lee is a notable inventor based in Daejeon, South Korea, recognized for his innovative work in the field of immunotherapy. He currently holds one patent that focuses on a specific monoclonal antibody designed to bind to lymphocyte-activation gene 3 (LAG-3), contributing to advancements in the treatment of various disorders.
Latest Patents
The patent granted to Dong Jung Lee is titled "Monoclonal antibody specifically binding to LAG-3 and use thereof." This invention involves a monoclonal antibody or an antigen-binding fragment that includes a heavy chain variable region and a light chain variable region essential for inhibiting the activity of LAG-3. The therapeutic potential of this invention lies in its ability to address various medical conditions associated with LAG-3, aspiring to aid in the development of effective immunotherapeutic agents.
Career Highlights
Dong Jung Lee is currently employed at Y-Biologics Inc., a company known for its pioneering research in the biotechnology sector. His role entails applying his inventive skills to foster advancements in therapeutic solutions that can change lives. Over the years, he has made significant strides in his field, establishing a reputation as an innovative thinker and a valuable contributor to scientific research.
Collaborations
Throughout his career, Dong Jung Lee has collaborated with talented colleagues, including Sang Pil Lee and Ji-Young Shin. These partnerships have facilitated the exchange of ideas and have been integral to the progression of innovative projects within the organization.
Conclusion
Dong Jung Lee's work exemplifies the critical role of inventors in shaping future medical therapies. His patent regarding the monoclonal antibody targeting LAG-3 holds promise for the future of immunotherapy, potentially transforming treatment strategies for associated disorders. Through his efforts and collaborations at Y-Biologics Inc., Dong Jung Lee continues to make impactful contributions to the field of biotechnology.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile